Innoviva Property, Plant, and Equipment 2010-2024 | INVA

Innoviva property, plant, and equipment from 2010 to 2024. Property, plant, and equipment can be defined as the sum of all net property, plant & Equipment fields. Where companies do not report a break down of plant, property, & equipment, the value is entered in this field alone.
Innoviva Annual Property, Plant, and Equipment
(Millions of US $)
2023 $0
2022 $0
2021 $0
2020 $0
2019 $0
2018 $0
2017 $0
2016 $0
2015 $0
2014 $0
2013 $10
2012 $9
2011 $10
2010 $10
2009 $13
Innoviva Quarterly Property, Plant, and Equipment
(Millions of US $)
2024-09-30 $1
2024-06-30 $0
2024-03-31 $0
2023-12-31 $0
2023-09-30 $0
2023-06-30 $0
2023-03-31 $0
2022-12-31 $0
2022-09-30 $0
2022-06-30 $0
2022-03-31 $0
2021-12-31 $0
2021-09-30 $0
2021-06-30 $0
2021-03-31 $0
2020-12-31 $0
2020-09-30 $0
2020-06-30 $0
2020-03-31 $0
2019-12-31 $0
2019-09-30 $0
2019-06-30 $0
2019-03-31 $0
2018-12-31 $0
2018-09-30 $0
2018-06-30 $0
2018-03-31 $0
2017-12-31 $0
2017-09-30 $0
2017-06-30 $0
2017-03-31 $0
2016-12-31 $0
2016-09-30 $0
2016-06-30 $0
2016-03-31 $0
2015-12-31 $0
2015-09-30 $0
2015-06-30 $0
2015-03-31 $0
2014-12-31 $0
2014-09-30 $0
2014-06-30
2014-03-31 $10
2013-12-31 $10
2013-09-30 $9
2013-06-30 $9
2013-03-31 $9
2012-12-31 $9
2012-09-30 $10
2012-06-30 $10
2012-03-31 $10
2011-12-31 $10
2011-09-30 $10
2011-06-30 $10
2011-03-31 $11
2010-12-31 $10
2010-09-30 $10
2010-06-30 $11
2010-03-31 $12
2009-12-31 $13
2009-09-30 $14
2009-06-30 $15
2009-03-31 $15
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.263B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $789.394B 81.76
Novo Nordisk (NVO) Denmark $481.063B 34.69
Johnson & Johnson (JNJ) United States $374.313B 15.18
AbbVie (ABBV) United States $352.544B 18.56
Merck (MRK) United States $260.350B 17.30
Novartis AG (NVS) Switzerland $217.584B 14.46
AstraZeneca (AZN) United Kingdom $199.957B 17.81
Pfizer (PFE) United States $151.422B 10.36
Sanofi (SNY) $130.241B 11.80